Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Neurocrine Biosciences Announces Conference Call and Webcast of Second Quarter 2024 Financial Results
Conference Call and Webcast Scheduled for Thursday, August 1
電話會議和網絡直播定於8月1日星期四舉行
SAN DIEGO, July 11, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its second quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a.m. Eastern Time) on August 1, 2024.
聖地亞哥，2024年7月11日 /PRNewswire/ — Neurocrine Biosciences, Inc.（納斯達克股票代碼：NBIX）今天宣佈，計劃於2024年8月1日太平洋時間上午5點（美國東部時間上午8點）舉行2024年第二季度財務業績電話會議和網絡直播。
The schedule for the press release and conference call / webcast is as follows:
新聞稿和電話會議/網絡直播的時間表如下：
|
• |
Q2 2024 Press Release: |
August 1, 2024 at 4:00 a.m. PT / 7:00 a.m. ET |
|
• |
Q2 2024 Conference Call: |
August 1, 2024 at 5:00 a.m. PT / 8:00 a.m. ET |
|
• |
Domestic Dial-In Number: |
800-445-7795 |
|
• |
International Dial-In Number: |
785-424-1699 |
|
• |
Conference ID: |
NBIX |
|
• |
2024 年第二季度新聞稿： |
2024 年 8 月 1 日太平洋時間凌晨 4:00 /美國東部時間上午 7:00 |
|
• |
2024 年第二季度電話會議： |
2024 年 8 月 1 日太平洋時間上午 5:00 /美國東部時間上午 8:00 |
|
• |
國內撥入號碼： |
800-445-7795 |
|
• |
國際撥入號碼： |
785-424-1699 |
|
• |
會議 ID： |
NBIX |
The webcast can also be accessed on Neurocrine Biosciences' website under Investors at . A replay of the webcast will be available on the website approximately one hour after the conclusion of the event and will be archived for approximately one month.
該網絡直播也可以在Neurocrine Biosciences網站上的 “投資者” 下觀看，網址爲。網絡直播的重播將在活動結束大約一小時後在網站上播放，並將存檔大約一個月。
About Neurocrine Biosciences
Neurocrine Biosciences is a leading neuroscience-focused, biopharmaceutical company with a simple purpose: to relieve suffering for people with great needs, but few options. We are dedicated to discovering and developing life-changing treatments for patients with under-addressed neurological, neuroendocrine, and neuropsychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, chorea associated with Huntington's disease, endometriosis* and uterine fibroids*, as well as a robust pipeline including multiple compounds in mid- to late-phase clinical development across our core therapeutic areas. For three decades, we have applied our unique insight into neuroscience and the interconnections between brain and body systems to treat complex conditions. We relentlessly pursue medicines to ease the burden of debilitating diseases and disorders, because you deserve brave science. For more information, visit neurocrine.com, and follow the company on LinkedIn, X (Formerly Twitter) and Facebook. (*in collaboration with AbbVie)
關於 Neurocrine 生物科學
Neurocrine Biosciences是一家專注於神經科學的領先生物製藥公司，其目標很簡單：減輕需求旺盛但選擇很少的人的痛苦。我們致力於爲未得到充分治療的神經系統、神經內分泌和神經精神疾病患者發現和開發改變生活的治療方法。該公司的多元化產品組合包括經美國食品藥品管理局批准的遲發性運動障礙、與亨廷頓氏病相關的舞蹈病、子宮內膜異位症*和子宮肌瘤*的治療方案，以及包括我們核心治療領域中後期臨床開發中的多種化合物的強大產品線。三十年來，我們運用對神經科學以及大腦和身體系統之間相互聯繫的獨特見解來治療複雜的疾病。我們堅持不懈地尋找藥物來減輕使人衰弱的疾病和失調的負擔，因爲你值得擁有勇敢的科學。欲了解更多信息，請訪問neurocrine.com，並在LinkedIn、X（前身爲推特）和Facebook上關注該公司。（*與 AbbVie 合作）
NEUROCRINE BIOSCIENCES, NEUROCRINE, and YOU DESERVE BRAVE SCIENCE are registered trademarks of Neurocrine Biosciences, Inc. The Neurocrine logo is a trademark of Neurocrine Biosciences, Inc.
NEUROCRINE BIOSCIENCES、NEUROCRINE 和 YOU RESERVE BRAVE SCIENCES, Inc. 的註冊商標。Neurocrine 徽標是 Neurocrine Biosciences, Inc. 的商標。
SOURCE Neurocrine Biosciences, Inc.
來源 Neurocrine 生物科學公司
譯文內容由第三人軟體翻譯。